Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02859766 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Patients With Neovascular AMD
A Phase 1 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02859766 is a Phase 1 study that has completed, run by Allergan. The registered enrollment target is 30 participants.
The verdict
NCT02859766, a Phase 1 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study will evaluate the safety and characterize the systemic pharmacokinetics (PK) of free and vascular endothelial growth factor (VEGF)-bound abicipar following single and multiple intravitreal injections of abicipar pegol in treatment-naïve patients with neovascular age-related macular degeneration (AMD).
Interventions
- DRUG Abicipar pegol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-12-07 |
| Est. Completion | 2017-10-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02859766
The ClinicalTrials.gov registry entry for NCT02859766 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abicipar pegol is the first listed.
NCT02859766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02859766 about?
NCT02859766 is a clinical study titled "Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Patients With Neovascular AMD". This study will evaluate the safety and characterize the systemic pharmacokinetics (PK) of free and vascular endothelial growth factor (VEGF)-bound abicipar following single and multiple intravitreal injections of abicipar pegol in treatment-naïve patients with neovascular age-related macular degene...
What is the current status of trial NCT02859766?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2016-12-07. Estimated completion is 2017-10-20.
What interventions are being tested in trial NCT02859766?
The interventions under investigation include: Abicipar pegol (DRUG).
Who is sponsoring clinical trial NCT02859766?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.